The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

November 6, 2024Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is $1.37, expectations were $0.14.

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

On Thursday, Emergent Biosolutions Inc (EBS) stock saw a modest uptick, ending the day at $11 which represents a slight increase of $1.80 or 19.57% from the prior close of $9.2. The stock opened at ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Wiles is co-chair at lobbying firm Mercury Public Affairs and has represented clients in the tobacco, junk food, insurance, ...

Emergent BioSolutions Inc. is heading into its next chapter — or “turnaround” phase, as its CEO describes it — after a strong ...

The U.S. overdose crisis and its racial disparities were overlooked in the election, as Black and Indigenous Americans face rising death rates.

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

Emergent BioSolutions (EBS) is up 23.7%, or $2.18 to $11.38. Published first on TheFly – the ultimate source for real-time, ...

Thursday after the company reported strong third-quarter results, lifting retail sentiment. Earnings per share for Q3 came in ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.